The Board of Directors of the Company at its meeting held today, August 5, 2026, has, inter alia, considered and approved:
a) the standalone and consolidated Unaudited Financial Results ....
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 05 Aug 2026, 07:52 PM IST · BSE ID: d53e759e-0d15-4439-925b-d50e179f50d2
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma reported its latest quarterly financial results and announced a plan to merge three of its subsidiary companies.
🤖 AI Summary
- Aurobindo Pharma's Board approved standalone Q1 FY26 results with Profit After Tax of ₹7,372.2 million.
- Consolidated Profit After Tax for Q1 FY26 stood at ₹19,977.8 million, showing a year-on-year increase.
- The Board approved a Scheme of Amalgamation for three wholly-owned subsidiaries: Eugia Steriles, Eugia SEZ, and Eugia Pharma Specialities.
- Standalone revenue from operations for Q1 FY26 was ₹27,995.1 million, a decline from ₹28,481.7 million year-on-year.
- Consolidated revenue from operations for Q1 FY26 reached ₹91,503.5 million, up from ₹78,681.4 million year-on-year.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Profit After Tax Q1 FY26
₹7,372.2 million
31.85%
Consolidated Profit After Tax Q1 FY26
₹19,977.8 million
27.21%
Standalone Revenue from Operations Q1 FY26
₹27,995.1 million
-1.71%
Consolidated Revenue from Operations Q1 FY26
₹91,503.5 million
16.30%
Standalone Basic EPS Q1 FY26
₹12.75
32.40%
🏢 How This Affects the Company
The proposed scheme of amalgamation consolidates three subsidiaries under Eugia Pharma Specialities Limited, streamlining the corporate structure related to sterile and SEZ operations.
Standalone Profit After Tax increased to ₹7,372.2 million in Q1 FY26 from ₹5,591.3 million in Q1 FY25. Consolidated Profit After Tax increased to ₹19,977.8 million from ₹15,735.6 million year-on-year.
The merger of subsidiaries indicates an effort to simplify operations and potentially integrate functions across Eugia Steriles Private Limited, Eugia SEZ Private Limited, and Eugia Pharma Specialities Limited.
The extinguishment of 5,423,728 equity shares through a buyback for ₹8,065.3 million reduced the paid-up equity share capital by ₹5.4 million, impacting capital structure.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with Basic EPS at ₹12.75 for Q1 FY26, compared to ₹9.63 in Q1 FY25. The buyback completed earlier reduced the paid-up equity share capital by ₹5.4 million.
🔍
Management Signal
The Board's decision to approve financial results and a subsidiary merger indicates a focus on operational consolidation and strategic alignment of business units.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
NCLT approval process for the proposed scheme of amalgamation
Updates on the integration of Eugia subsidiaries post-merger
Q2 FY27 financial results for revenue and profit trends
LOW RISK
The filing indicates strong Q1 FY26 profit growth and a planned internal restructuring.
💡 Investor Takeaway
Aurobindo Pharma reported Q1 FY26 standalone Profit After Tax of ₹7,372.2 million, a 31.85% increase from Q1 FY25, and consolidated Profit After Tax of ₹19,977.8 million, up 27.21%. The Board approved a scheme for merging three Eugia subsidiaries.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Profit After Tax for Q1 FY26 increased by 31.85% to ₹7,372.2 million compared to ₹5,591.3 million in Q1 FY25.
- Consolidated Profit After Tax for Q1 FY26 grew by 27.21% to ₹19,977.8 million from ₹15,735.6 million in Q1 FY25.
⚠️ Concerns
- Standalone Revenue from Operations for Q1 FY26 decreased by 1.71% to ₹27,995.1 million from ₹28,481.7 million in Q1 FY25.
- Changes in inventories of finished goods, stock-in-trade, and work-in-progress showed a negative figure of (₹480.5) million in standalone Q1 FY26 results.
❓ Frequently Asked Questions
What was Aurobindo Pharma's standalone Profit After Tax for Q1 FY26?
Aurobindo Pharma's standalone Profit After Tax for the quarter ended June 30, 2026, was ₹7,372.2 million.
What was the consolidated Profit After Tax for Aurobindo Pharma in Q1 FY26?
The consolidated Profit After Tax for Aurobindo Pharma for the quarter ended June 30, 2026, was ₹19,977.8 million.
What scheme of amalgamation did Aurobindo Pharma's Board approve?
Aurobindo Pharma's Board approved a scheme to merge Eugia Steriles Private Limited and Eugia SEZ Private Limited with Eugia Pharma Specialities Limited, which are all wholly-owned subsidiaries.
How did standalone revenue from operations change for Aurobindo Pharma in Q1 FY26 compared to Q1 FY25?
Standalone revenue from operations for Q1 FY26 was ₹27,995.1 million, a decrease from ₹28,481.7 million in Q1 FY25.
What was Aurobindo Pharma's standalone Basic Earnings Per Share (EPS) for Q1 FY26?
Aurobindo Pharma's standalone Basic Earnings Per Share (EPS) for the quarter ended June 30, 2026, was ₹12.75.
Questions based on this BSE filing only. For information purposes.